Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin

Doxorubicin is a first-line therapy for patients with unresectable advanced soft tissue sarcoma (STS). However, because of cardiotoxicities, it is not used for patients with cardiac problems. Eribulin has exhibited efficacy for advanced STS in second- or later-line treatments. In the present study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuchihashi, Kenji, Kusaba, Hitoshi, Yoshihiro, Tomoyasu, Fujiwara, Toshifumi, Setsu, Nokitaka, Endo, Makoto, Matsumoto, Yoshihiro, Imajima, Takashi, Shinohara, Yudai, Ito, Mamoru, Yamaga, Satoru, Tanoue, Kenro, Arimizu, Kohei, Ohmura, Hirofumi, Hanamura, Fumiyasu, Yamaguchi, Kyoko, Isobe, Taichi, Ariyama, Hiroshi, Nakashima, Yasuharu, Akashi, Koichi, Baba, Eishi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708971/
https://www.ncbi.nlm.nih.gov/pubmed/33262403
http://dx.doi.org/10.1038/s41598-020-77898-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7708971/
https://www.ncbi.nlm.nih.gov/pubmed/33262403
http://dx.doi.org/10.1038/s41598-020-77898-y

Ejemplares similares